New York, NYNCT07326709Now EnrollingIRB Ready

Huntington Disease Clinical Trial in New York, NY

Access cutting-edge huntington disease treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access huntington disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related huntington disease treatment provided free

Apply for This New York Location

Check if you qualify for this huntington disease clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Huntington Disease Study in New York

The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Signed informed consents must be obtained prior to participation in the study
Ambulatory male or female participants between 21 to 70 years of age, inclusive, on the day of Informed Consent signature
Genetically confirmed HD diagnosis with a cytosine-adenine-guanine (CAG) repeat length of 40 or above. Participants must have prior genetic confirmation and known CAG repeat length obtained prior to screening.
Meets all of the following criteria:
UHDRS IS score ≥90
UHDRS TFC score = 13
UHDRS TMS score = 7-25, inclusive
CAP100 ≥ 70 Calculation: CAP = Age at study entry × (CAG length - 30) / 6.49

Exclusion Criteria

History of gene therapy or cell transplantation or any other experimental brain surgery for the treatment of HD
Serologic evidence for active viral hepatitis as indicated by:
positive anti-HBc IgM
positive anti-HBc IgG confirmed by positive HBsAg and/or HBV DNA
positive HCV ab test confirmed by positive HCV RNA
Immunodeficiency diseases, including a positive human immunodeficiency virus (HIV) test result
History or current diagnosis of ECG or cardiac abnormalities indicating significant risk of safety for participants such as:
Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker
History of familial long QT syndrome or known family history of Torsade de Pointes
Women of childbearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks before taking study treatment. In the case of oophorectomy alone, the reproductive status of the woman needs to have been confirmed by follow-up hormone level assessment. o WOCBP are excluded unless they are using highly effective methods of contraception (failure rate \< 1% per year) while taking study treatment and for 8 months after stopping study treatment.
Pregnant or nursing (breastfeeding) women Other protocol defined inclusion/exclusion criteria may apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07326709) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Huntington Disease Treatment Options in New York, NY

If you're searching for huntington disease treatment options in New York, NY, this clinical trial (NCT07326709) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced huntington disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all huntington disease clinical trials near you to find additional studies recruiting in your area.

More Huntingtons Disease Trials in New York, NY

See all huntingtons disease clinical trials recruiting in New York — not just this study.

Browse Huntingtons Disease Trials in New York →

Browse More Trials by Condition

Huntingtons Disease TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY